who should not take semaglutide for weight loss What Happens After Stopping Semaglutide? 🌿 The Truth About Semaglutide

Expected Outcomes Based on Clinical Evidence FDA-approved semaglutide clinical trial data: The STEP 1 trial demonstrated 14.9% average body weight loss over 68 weeks when combined with reduced-calorie diet and increased physical activity

Tirzepatide also provides strong fatty liver clearance, but not at the sheer velocity demonstrated by the triple agonist

Mind Your Portions The most important rule is to watch the serving size

Summary Keywords glucagon like peptide-1, irritable bowel syndrome, pain, IBS, agonist Citation Mostafa MEA and Alrasheed T (2025) Improvement of irritable bowel syndrome with glucagon like peptide-1 receptor agonists: a systematic review and meta-analysis